GSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for the continued development and ...

Patients with eosinophilic granulomatosis with polyangiitis experienced significant improvements in a variety of outcomes ...

The U.S. Food and Drug Administration extended the review of KalVista Pharmaceuticals' drug for a type of hereditary swelling ...

GSK just hit one of its main objectives for 2025 after getting FDA approval of anti-IL-5 antibody Nucala as a treatment for chronic obstructive pulmonary disease (COPD). Nucala (mepolizumab ...

New study results with GSK's anti-IL-5 antibody Nucala in chronic obstructive pulmonary disease (COPD) have been published, just ahead of an FDA decision on the new indication scheduled for 7th May.

The benefits of 52-week biologic therapy on asthma control and lung function are observed in both never smokers and ...

The Food and Drug Administration has gone all in on AI since Martin Makary, M.D., took over the agency, most recently ...

Ohtuvayre's rapid US launch boosts Verona's growth with Q1 2025 sales up 95%. Read more on VRNA stock's blockbuster potential ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets ...

At close: 3:30:02 PM GMT+5:30 ...